Characterization of a duocarmycin-DNA adduct-recognizing protein in cancer cells

Cancer Research

Volumn 59, Issue 21, 1999, Pages 5417-5420

  Asai, Akira ^a   Yano, Keiichi ^a   Mizukami, Tamio ^a   Nakano, Hirofumi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DISTAMYCIN A; DOXORUBICIN; DUOCARMYCIN A; RACHELMYCIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; DNA ADDUCT; DNA ALKYLATION; DNA CONFORMATION; DNA DRUG COMPLEX; DRUG DNA BINDING; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTHRAMYCIN; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BINDING, COMPETITIVE; CATTLE; CELL NUCLEUS; DNA; DNA ADDUCTS; DNA-BINDING PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HELA CELLS; HUMANS; INDOLES; LEUCOMYCINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDES; PYRROLES; THYMUS GLAND; TUMOR CELLS, CULTURED;

EID: 0033229931     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Boger, D. L., and Johnson, D. S. CC-1065 and duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc. Natl. Acad. Sci. USA, 92: 3542-3649, 1995.
2. Kobayashi, E., Okamoto, A., Asada, M., Okabe, M., Nagamura, S., Asai, A., Saito, H., Gomi, K., and Hirata, T. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Cancer Res., 54: 2404-2410, 1994.
3. Alberts, S. R., Erlichman, C., Reid, J. M., Sloan, J. A., Ames, M. M., Richardson, R. L., and Goldberg, R. M. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin. Cancer Res., 4: 2111-2117, 1998.
4. Wrasidlo, W., Johnson. D. S., and Boger, D. L. Induction of endonucleolytic DNA fragmentation and apoptosis by the duocarmycins. Bioorg. Med. Chem. Lett., 4: 631-636, 1994.
5. Lippard, S. J. Chemistry and molecular biology of platinum anticancer drugs. Pure Appl. Chem., 59: 731-742, 1987.
6. Zamble, D. B., and Lippard, S. J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci., 20: 435-439, 1995.
7. Ohndorf, U., Rould, M. A., He, Q., Pabo, C. O., and Lippard, S. J. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature (Lond.), 399: 708-712, 1999.
8. Brown, S. J., Kellett, P. J., and Lippard, S. J. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science (Washington DC), 261: 603-605, 1993.
9. Martinez, E. J., Owa, T., Schreiber, S. L., and Corey, E. J. Phthalascidin, a synthetic antitumor agent with potency and mode of action to ecteinascidin 743. Proc. Natl. Acad. Sci. USA, 96: 3496-3501, 1999.
10. Takebayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G., and Pommier, Y. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. USA, 96: 7196-7201, 1999.
11. Dignam, J. D., Lebovitz, M. L., and Roeder, R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11: 1475-1489, 1983.
12. Kumar, S., Rosely, L., and Tomasz, M. Recognition of specific DNA sequences by mitomycin C for alkylation. Biochemistry, 31: 1399-1407, 1983.
13. Reynolds, V. L., Molineux, I. J., Kaplan, D. J., Swenson, D. H., and Hurley, L. H. Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry, 24: 6228-6237, 1985.
14. Asai, A., Nagamura, S., and Saito, H. A novel property of duocarmycin and its analogues for covalent reaction with DNA. J. Am. Chem. Soc., 116: 4171-4177, 1994.
15. Okamoto, A., Asai, A., Saito, H., Okabe, M., and Gomi, K. Differential effect of duocarmycin A and its novel derivative DU-86 on DNA strand breaks in HeLa S3 cells. Jpn. J. Cancer Res., 85: 1304-1311, 1994.
16. Sun, D., Lin, C. H., and Hurley, L. H. A-tract and (+)-CC-1065-induced bending of DNA. Comparison of structural feature using non-denaturating gel analysis, hydroxyl-radical footprinting, and high-field NMR. Biochemistry, 32: 4487-4495, 1993.
17. Lee, C. S., Sun, D., Kizu, R., and Hurley, L. H. Determination of the structure features of (+)-CC-1065 that are responsible for bending and winding of DNA. Chem. Res. Toxicol., 4: 203-213, 1991.
18. Kizu, R., Draves, P. H., and Hurley, L. H. Correlation of DNA sequence specificity of anthramycin and tomaymycin with reaction kinetics and bending of DNA. Biochemistry, 32: 8712-8722, 1993.
19. Pelton, J. G., and Wemmer, D. E. Structural characterization of a 2:1 distamycin A-d(CGCAAATTGGC) complex by two-dimensional NMR. Proc. Natl. Acad. Sci. USA, 86: 5723-5727, 1989.
20. Colella, G., Bonfanti, M., D'Incalci, M., and Broggini, M. Characterization of a protein recognizing minor groove binders-damaged DNA. Nucleic Acids Res., 24: 4227-4233, 1996.
21. Bellon, S. F., Coleman, J. H., and Lippard, S. J. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry, 30: 8026-8035, 1991.
22. Chu, G., and Chang, E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc. Natl. Acad. Sci. USA, 87: 3324-3327, 1990.
23. Jacobson, M. K., Twehous, D., and Hurley, L. H. Depletion of nicotinamide adenine dinucleotide in normal and xeroderma pigmentosum fibroblast cells by the antitumor drug CC-1065. Biochemistry, 25: 5929-5932, 1986.
24. McA'Nutly, M. M., Whitehead, J. P., and Lippard, S. J. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo. Biochemistry, 35: 6089-6099, 1996.